IFNG and asthma: In contract, there was no significant differences between asthma and control groups in the percentage of CD4+ cells expressing Foxp3 (CD4+Foxp3+ cells) [4.4% (0.8–12.5%) vs 6.8% (2.1–12.6%)], CD4+Foxp3+IFN-γ+ cells [2.1% (0.3–5.6%) vs 1.8% (0.6–3.4%)], CD4+Foxp3+TNF-α+ cells [1.6% (0.4–4.3%) vs 1.8% (0.8–5.4%)], CD4+Foxp3+IL-4+ cells [1.9% (0.2–8.7%) vs 1.6% (0.4–4.2%)], CD4+Foxp3+IL-10+ cells [2.0% (0.1–7.5%) vs 1.1% (0.3–5.7%)] or CD4+Foxp3+CD25+ cells [2.3% (0.1–10.7%) vs 2.6% (0.7–4.3%)].